Physician profile
Stephen R Buksh
NPI 1427053396
$4,020.87
in general payments reported to CMS, 2019-2025
38 companies · $964 in 2025
The $964 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $286 · 2021: $493 · 2022: $222 · 2023: $497 · 2024: $856 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $624.19 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $475.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $430.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $293.28 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $234.28 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $196.68 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.89 | 2019-2024 | Jardiance |
| Pfizer INC. | $183.55 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.83 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $164.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.65 | 2021-2025 | |
| Lilly USA, LLC | $104.25 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $98.25 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $85.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $77.15 | 2019-2023 | Xarelto |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Buksh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.